Molecular markers to predict response to therapy

Semin Oncol. 2013 Aug;40(4):444-58. doi: 10.1053/j.seminoncol.2013.05.005.

Abstract

Currently approved treatments for metastatic renal cell carcinoma (RCC) include vascular endothelial growth factor (VEGF)-blocking agents, mammalian target of rapamycin (mTOR) inhibitors, and cytokine therapy. In the near future, we are likely to add immune checkpoint blocking agents to this list. As we develop treatment platforms around each therapeutic class, determining which drug is best for a particular patient becomes increasingly important. At this point, we do not have validated predictive biomarkers for patients with RCC. Here, we discuss the logistical challenges surrounding biomarker development, summarize the current crop of biomarker candidates, and explore potential avenues for the development of more effective predictive tools for patients with advanced RCC.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antigens, Neoplasm / genetics
  • Bevacizumab
  • Biomarkers, Tumor
  • Carbonic Anhydrase IX
  • Carbonic Anhydrases / genetics
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / genetics
  • Carcinoma, Renal Cell / immunology
  • Carcinoma, Renal Cell / pathology
  • Gene Dosage
  • Humans
  • Immunotherapy
  • Indazoles
  • Indoles / therapeutic use
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / genetics
  • Kidney Neoplasms / immunology
  • Kidney Neoplasms / pathology
  • Mutation
  • Neoplastic Cells, Circulating
  • Niacinamide / analogs & derivatives
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use
  • Phosphatidylinositol 3-Kinases / physiology
  • Polymorphism, Genetic
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Sorafenib
  • Sulfonamides / therapeutic use
  • Sunitinib
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Von Hippel-Lindau Tumor Suppressor Protein / genetics

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Indazoles
  • Indoles
  • Phenylurea Compounds
  • Pyrimidines
  • Pyrroles
  • Sulfonamides
  • Niacinamide
  • Bevacizumab
  • pazopanib
  • Sorafenib
  • Von Hippel-Lindau Tumor Suppressor Protein
  • TOR Serine-Threonine Kinases
  • CA9 protein, human
  • Carbonic Anhydrase IX
  • Carbonic Anhydrases
  • VHL protein, human
  • Sunitinib